| abstract |
The present invention relates to a dapagliflozin L-proline-containing pharmaceutical composition. Specifically, the dapagliflozin L-proline-containing pharmaceutical composition, according to the present invention, exhibits excellent elution properties even when the d(0.9) of the dapagliflozin L-proline has a large particle size distribution of at least 60μm, and provides the advantages of enabling a simple production process and a small loss of active ingredients. Thus, the pharmaceutical composition, according to the present invention, may be used as a preventive or therapeutic agent, for diabetes, diabetes-related diseases and diabetes complications, which has an excellent elution rate and bioabsorption rate. |